CNBC September 17, 2024
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.
Good afternoon! Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating.
But can the Swiss company develop drugs that can compete with that duopoly?
The answer isn’t clear yet.
We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.
But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised...
Today's Sponsors
Today's Sponsor